Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

High-throughput fragment screening by affinity LC-MS.

Duong-Thi MD, Bergström M, Fex T, Isaksson R, Ohlson S.

J Biomol Screen. 2013 Feb;18(2):160-71. doi: 10.1177/1087057112459271.

PMID:
22983162
2.

Weak affinity chromatography as a new approach for fragment screening in drug discovery.

Duong-Thi MD, Meiby E, Bergström M, Fex T, Isaksson R, Ohlson S.

Anal Biochem. 2011 Jul 1;414(1):138-46. doi: 10.1016/j.ab.2011.02.022.

PMID:
21352794
3.

Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels.

Hämäläinen MD, Zhukov A, Ivarsson M, Fex T, Gottfries J, Karlsson R, Björsne M.

J Biomol Screen. 2008 Mar;13(3):202-9. doi: 10.1177/1087057108314651.

PMID:
18270366
4.

Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.

Kobayashi M, Retra K, Figaroa F, Hollander JG, Ab E, Heetebrij RJ, Irth H, Siegal G.

J Biomol Screen. 2010 Sep;15(8):978-89. doi: 10.1177/1087057110375614.

PMID:
20817886
5.

SPR-based fragment screening: advantages and applications.

Neumann T, Junker HD, Schmidt K, Sekul R.

Curr Top Med Chem. 2007;7(16):1630-42. Review.

PMID:
17979772
6.

Fragment-based drug design: computational & experimental state of the art.

Hoffer L, Renaud JP, Horvath D.

Comb Chem High Throughput Screen. 2011 Jul;14(6):500-20. Review.

PMID:
21521152
7.

Multiple ligand detection and affinity measurement by ultrafiltration and mass spectrometry analysis applied to fragment mixture screening.

Qin S, Ren Y, Fu X, Shen J, Chen X, Wang Q, Bi X, Liu W, Li L, Liang G, Yang C, Shui W.

Anal Chim Acta. 2015 Jul 30;886:98-106. doi: 10.1016/j.aca.2015.06.017.

PMID:
26320641
8.

Toward high-throughput drug screening on a chip-based parallel affinity separation platform.

Ohlson S, Duong-Thi MD, Bergström M, Fex T, Hansson L, Pedersen L, Guazotti S, Isaksson R.

J Sep Sci. 2010 Sep;33(17-18):2575-81. doi: 10.1002/jssc.201000314.

PMID:
20730836
9.

High impact technologies for natural products screening.

Koehn FE.

Prog Drug Res. 2008;65:175, 177-210. Review.

PMID:
18084916
10.

Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.

Bergsdorf C, Ottl J.

Expert Opin Drug Discov. 2010 Nov;5(11):1095-107. doi: 10.1517/17460441.2010.524641. Review.

PMID:
22827747
11.

High-throughput screening for enzyme inhibitors using frontal affinity chromatography with liquid chromatography and mass spectrometry.

Ng ES, Yang F, Kameyama A, Palcic MM, Hindsgaul O, Schriemer DC.

Anal Chem. 2005 Oct 1;77(19):6125-33.

PMID:
16194069
12.

Fragment screening of cyclin G-associated kinase by weak affinity chromatography.

Meiby E, Knapp S, Elkins JM, Ohlson S.

Anal Bioanal Chem. 2012 Nov;404(8):2417-25. doi: 10.1007/s00216-012-6335-6.

13.

Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.

Riccardi Sirtori F, Caronni D, Colombo M, Dalvit C, Paolucci M, Regazzoni L, Visco C, Fogliatto G.

Eur J Pharm Sci. 2015 Aug 30;76:83-94. doi: 10.1016/j.ejps.2015.05.001.

PMID:
25952103
14.

Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.

Chen D, Ranganathan A, IJzerman AP, Siegal G, Carlsson J.

J Chem Inf Model. 2013 Oct 28;53(10):2701-14. doi: 10.1021/ci4003156.

PMID:
23971943
15.

Biosensor-based small molecule fragment screening with biolayer interferometry.

Wartchow CA, Podlaski F, Li S, Rowan K, Zhang X, Mark D, Huang KS.

J Comput Aided Mol Des. 2011 Jul;25(7):669-76. doi: 10.1007/s10822-011-9439-8.

PMID:
21660516
16.

Hsp90 inhibitors and drugs from fragment and virtual screening.

Roughley S, Wright L, Brough P, Massey A, Hubbard RE.

Top Curr Chem. 2012;317:61-82. doi: 10.1007/128_2011_181. Review.

PMID:
21647838
17.

Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.

Drinkwater N, Vu H, Lovell KM, Criscione KR, Collins BM, Prisinzano TE, Poulsen SA, McLeish MJ, Grunewald GL, Martin JL.

Biochem J. 2010 Oct 1;431(1):51-61. doi: 10.1042/BJ20100651.

PMID:
20642456
18.

Screening Ligands by X-ray crystallography.

Davies DR.

Methods Mol Biol. 2014;1140:315-23. doi: 10.1007/978-1-4939-0354-2_23.

PMID:
24590727
19.

Fragment-based drug discovery using rational design.

Jhoti H.

Ernst Schering Found Symp Proc. 2007;(3):169-85. Review.

PMID:
18510103
20.

From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.

Giannetti AM.

Methods Enzymol. 2011;493:169-218. doi: 10.1016/B978-0-12-381274-2.00008-X.

PMID:
21371592
Items per page

Supplemental Content

Support Center